Afya Limited Class A Common Shares (AFYA)
Afya Limited is a healthcare education company primarily focused on providing medical, dental, and other health sciences training in Latin America. The company operates through a network of universities and professional training centers, offering undergraduate and postgraduate programs to meet the growing demand for healthcare professionals in the region. Afya aims to expand access to quality health education and improve healthcare quality through its educational offerings.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| April 4, 2025 | $0.23 | 2025-03-26 | 2025-03-26 |
Dividends Summary
- Afya Limited Class A Common Shares has issued 1 dividend payments over the past 0 years
- The most recent dividend was paid 169 days ago, on April 4, 2025
- The highest dividend payed out to investors during this period was $0.232049 per share
- The average dividend paid during this period was $0.23 per share.
Company News
The article discusses 5 top small-cap stocks that are Zacks Rank #1 (Strong Buy) or #2 (Buy) stocks, including Soundhound AI, Afya, Castle Biosciences, TriMas, and Immersion. The article provides an overview of each company's business, market cap, stock performance, and earnings growth outlook.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised Synopsys, Inc. (NASDAQ: SNPS) price target from $540 to $600. Keybanc analyst Jason Celino maintained an Overweight rating. Synopsys shares rose 0.3% to close at $542.69 on Friday. See how other analysts view this stock. Berenberg cut the price target for Corteva, Inc. (NYSE: CTVA) from $63 to $52. Berenberg analyst Aron Ceccarelli downgraded the stock from Buy to Hold. Corteva shares rose 0.7% to close at $46.67 on Friday. See how other analysts view this stock. UBS increased the price target for Teva Pharmaceutical Industries Limited (NYSE: TEVA) from $11 to $13. UBS analyst Ashwani Verma upgraded the stock from Neutral to Buy. Teva Pharmaceutical shares gained 2% to $9.74 in ...Full story available on Benzinga.com
Investors found enough to like in the company's third-quarter results to buy into the shares.
Ron Baron's 13F portfolio value decreased from $40.75B to $31.14B this quarter. Click here to read more about BAMCO's holdings and trades for Q2 2022.
NOVA LIMA, MINAS GERAIS, Brazil, July 23, 2021 (GLOBE NEWSWIRE) -- Afya Limited, or “Afya” (Nasdaq: AFYA) announced today that the resolutions set out in its Notice of Annual General Meeting dated June 28, 2021 were duly passed at its Annual General Meeting held today: (1) the approval and ratification of Afya’s financial statements as of and for the fiscal year ended December 31, 2020; and (2) the approval of the Amended and Restated Memorandum and Articles of Association available at Afya’s website at https://ir.afya.com.br, subject to and with effect from Closing (as that term is defined in the share purchase agreement dated on or about June 7, 2021 between Crescera Educacional II Fundo de Investimento em Participações Multiestratégia and Erste WV Gtersloh Gmbh).